A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.

ABSTRACT:

Background

Ticagrelor is one of the most recent antiplatelet drugs to be approved to treat ischemic heart disease. Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA.

Objectives

We evaluated the safety regarding hemorrhagic complications (as a primary endpoint) and the efficacy (as a secondary endpoint) of a 180-mg loading dose of ticagrelor given within 9 h from the onset of the first-ever non-cardioembolic ischemic stroke.

Methods

We conducted our study on patients aged 18-75 years who presented with their first clinically manifested non-cardioembolic ischemic stroke and were recruited from the emergency department OF Kafr El-Sheik University Hospitals, Egypt. Eligible patients randomly

SUBMITTER: Aref HM 

PROVIDER: S-EPMC9842543 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature